Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
GlaxoSmithKline plc (LSE/NYSE.
Sanofi to halt bladder cancer drug production
Sanofi to halt bladder cancer drug production
Sanofi Pasteur will stop producing its version of the bladder-cancer drug treatment BCG, sold as TheraCys/ImmuCyst, in mid-2017, the company said in a statement Nov.
Novel tool to may lead to Zika vaccines
Novel tool to may lead to Zika vaccines
HOUSTON.
Last-line antibiotics are failing
Last-line antibiotics are failing
On the occasion of the 9th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) is releasing its latest EU-wide data on antibiotic resistance and an...
Cancer vaccines market will soar to $7.5 billion by 2022, says GBI Research
Cancer vaccines market will soar to $7.5 billion by 2022, says GBI Research
The cancer vaccines market is set to almost triple from $2.
Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program
Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program
PALO ALTO, CA, USA I November 14, 2016 I Eiger BioPharmaceuticals, Inc, (EIGR) today announced an update on presentations of data from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis ...
Heartburn drugs may increase the risk of stroke
Heartburn drugs may increase the risk of stroke
NEW ORLEANS — Popular heartburn medication may increase the risk of ischemic stroke.
ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)
ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)
MOUNTAIN VIEW, CA, USA I ChemoCentryx, Inc.
CRISPR gene-editing tested in a person for the first time
CRISPR gene-editing tested in a person for the first time
A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique.
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
Basel, 15 November 2016.
Myelofibrosis market will exceed $1 billion by 2025, says GlobalData
Myelofibrosis market will exceed $1 billion by 2025, says GlobalData
The myelofibrosis market is expected to almost double in value from $545.
FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's Keytruda
FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's Keytruda
Thursday was quite the day for Bristol-Myers Squibb’s Opdivo.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand